All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
BIRMA trial: Is BRAF and MEK inhibition successful in relapsed MM?
Video series
ASH 2020 | Novel therapies for RRMM
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Marc S. Raab, Heidelberg University Hospital, Heidelberg, DE, about the BIRMA trial. We asked, Is BRAF and MEK inhibition successful in relapsed multiple myeloma (MM)?
The activating BRAF V600E mutation is a rare mutation that occurs in 4–8% of patients in the refractory setting of MM. In this video, Raab discusses the BIRMA trial, evaluating the combined BRAF and MEK inhibition in patients with heavily pretreated MM with BRAF V600E mutation.
Video series
ASH 2020 | Novel therapies for RRMM
Your opinion matters
47 votes - 9 days left ...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox